AmerisourceBergen Corp. (ABC US) sank 3.2 percent, the second-biggest drop in the Standard & Poor's 500 Index, to $37.36. The drug distributor said Chief Financial Officer Michael DiCandilo left the company.
Arch Coal Inc. (ACI US) declined 4.4 percent, the biggest drop in the Russell 1000 Index, to $13.76. The coal mining company was cut to "hold" from "buy" at Brean Murray Carret & Co.
Chelsea Therapeutics International Ltd. (CHTP US) dropped the most in the Russell 2000 Index, sinking 36 percent to $3.19. The biotechnology company said the Food and Drug Administration has placed "increased emphasis on safety data" in its review of the company's Northera drug.
Chesapeake Energy Corp. (CHK US) climbed 1.5 percent to $22.46, after rallying to $23.32, the highest intraday price since Jan. 25. The most active U.S. natural-gas driller said it plans to raise as much as $12 billion this year from asset sales and joint ventures as it seeks to generate enough cash to meet its drilling expenses.
Complete Genomics Inc. (GNOM US) rose the most in the Russell 2000 Index, rallying 39 percent to $4.58. The makers of genomic analysis tools said it was picked by Mayo Clinic to provide human genome sequencing.
Dana Holding Corp. (DAN US) climbed 4.6 percent to $15.97 and reached $16.40 earlier, the highest intraday price since Aug. 2. The maker of vehicle axles and other driveline components may rise this year as it expands in emerging markets and makes environmentally friendly products, Barron's reported, citing Gabelli & Co. analyst Brian Sponheimer.
Diebold Inc. (DBD US) rose 9.1 percent to $37.91 after touching $38.50, the highest intraday price since September 2008. The maker of automated bank-teller machines forecast 2012 earnings per share of $2.30 to $2.50 a share, compared with the average analyst estimate of $2.31, and forecast sales growth of at least 3 percent, beating the average estimate of 2 percent.
Monster Worldwide Inc. (MWW US) fell 3.7 percent to $6.95 after slipping to $6.92, the lowest intraday price since Nov. 29. The world's largest online-recruiting company was cut to "sell" from "neutral" at Citigroup Inc., which cited increasing competition.
Regeneron Pharmaceuticals Inc. (REGN US) jumped 13 percent, the most in the Russell 1000 Index, to $114.85. The drugmaker reported a fourth-quarter adjusted loss per share that was narrower than the average analyst estimate and increased its 2012 U.S. sales forecast for its Eylea treatment for a blindness-causing eye disorder to at least $250 million from no more than $160 million. (source Bloomberg)For the latest updates on the stock market, visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
No comments:
Post a Comment